Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Hematologic Neoplasms 2Rare Diseases 1Neurologic Manifestations 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myasthenia Gravis 1Mental Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Infections 1Burkitt Lymphoma 1Agammaglobulinemia 1

Interventions

XENP 1595 2Standard of Care 2Selective Serotonin Reuptake Inhibitors 1Plasma Exchange 1Methylphenidate 1Memory and Learning Tests 1Interviews as Topic 1Immunoglobulins 1Forest Therapy 1Dialectical Behavior Therapy 1Cognitive Behavioral Therapy 1Clomipramine 1Citalopram 1Behavior Therapy 1Animal Assisted Therapy 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mental Disorders × Immunoglobulins × Clear all
NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡